Clinical Characteristics and Surgical Outcomes of Patients Receiving Perioperative Pembrolizumab in KEYNOTE-671

BACKGROUND: The phase 3 KEYNOTE-671 study (NCT03425643) demonstrated significantly improved event-free survival (EFS) and overall survival with neoadjuvant pembrolizumab plus chemotherapy followed by surgery and adjuvant pembrolizumab versus neoadjuvant chemotherapy and surgery for early-stage non‒small-cell lung cancer (NSCLC). We describe participant characteristics, surgical outcomes, and EFS in surgically relevant subgroups. METHODS: Participants with untreated, resectable, stage II‒IIIB (N2) NSCLC were randomized 1:1 to neoadjuvant pembrolizumab 200 mg or placebo plus cisplatin-based chemotherapy every 3 weeks for 4 cycles, then surgery and adjuvant pembrolizumab or placebo for 13 cycles. Surgery was performed

• Liberman, M.
• Jones, D. R.
• Wakelee, H.
• Gao, S.
• Halmos, B.
• Nadal, E.
• Łowczak, A.
• Reck, M.
• Novello, S.
• Matias, D.
• Luft, A.
• Hui, R.
• Lee, S. H.
• Tsuboi, M.
• Kato, T.
• Zhu, Y.
• Weksler, B.
• Jensen, E.
• Samkari, A.
• Keller, S. M.
• Spicer, J. D.